MRI not a useful and effective modality for diagnosing liver cancer: Study

Published On 2022-05-20 14:15 GMT   |   Update On 2022-05-20 14:15 GMT

According to a recent study published in the Cochrane, magnetic resonance imaging (MRI) scans are not that effective for scanning liver cancer. Hepatocellular carcinoma occurs mostly in people with chronic liver disease and ranks sixth in terms of the global incidence of cancer and third in terms of cancer deaths. In clinical practice, magnetic resonance imaging (MRI) is used as...

Login or Register to read the full article

According to a recent study published in the Cochrane, magnetic resonance imaging (MRI) scans are not that effective for scanning liver cancer.

Hepatocellular carcinoma occurs mostly in people with chronic liver disease and ranks sixth in terms of the global incidence of cancer and third in terms of cancer deaths. In clinical practice, magnetic resonance imaging (MRI) is used as a second-line diagnostic imaging modality to confirm the presence of focal liver lesions suspected as hepatocellular carcinoma on prior diagnostic tests such as abdominal ultrasound or alpha-fetoprotein, or both, either in surveillance programmes or in clinical settings. According to current guidelines, a single contrast-enhanced imaging study (computed tomography (CT) or MRI) showing typical hallmarks of hepatocellular carcinoma in people with cirrhosis is considered valid to diagnose hepatocellular carcinoma. The detection of hepatocellular carcinoma amenable to surgical resection could improve the prognosis. However, a significant number of hepatocellular carcinomas do not show typical hallmarks on imaging modalities, and hepatocellular carcinoma may, therefore, be missed. There is no clear evidence of the benefit of surveillance programmes in terms of overall survival: the conflicting results can be a consequence of inaccurate detection, ineffective treatment, or both. Assessing the diagnostic accuracy of MRI may clarify whether the absence of benefit could be related to underdiagnosis. Furthermore, an assessment of the accuracy of MRI in people with chronic liver disease who are not included in surveillance programmes is needed to rule out or diagnose hepatocellular carcinoma.

Objectives:

Primary: To assess the diagnostic accuracy of MRI for the diagnosis of hepatocellular carcinoma of any size and at any stage in adults with chronic liver disease.

Secondary: To assess the diagnostic accuracy of MRI for the diagnosis of resectable hepatocellular carcinoma in adults with chronic liver disease and to identify potential sources of heterogeneity in the results.

They searched the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Hepato-Biliary Group Diagnostic Test of Accuracy Studies Register, the Cochrane Library, MEDLINE, Embase, and three other databases to 9 November 2021. We manually searched articles retrieved, contacted experts, handsearched abstract books from meetings held during the last 10 years, and searched for literature in OpenGrey (9 November 2021). Further information was requested by e-mails, but no additional information was provided. No data was obtained through correspondence with investigators. We applied no language or document-type restrictions.

Studies assessing the diagnostic accuracy of MRI for diagnosing hepatocellular carcinoma in adults with chronic liver disease, with cross-sectional designs, using one of the acceptable reference standards, such as pathology of the explanted liver and histology of resected or resected or biopsied focal liver lesion with at least a six-month follow-up.

At least two review authors independently screened studies, extracted data, and assessed the risk of bias and applicability concerns using the QUADAS-2 checklist. They presented the sensitivity and specificity results using paired forest plots, and we tabulated the results. They used a hierarchical meta-analysis model where appropriate. We presented uncertainty of the accuracy estimates using 95% confidence intervals (CIs). They double-checked all data extractions and analyses.

Main results:

  • They included 34 studies with 4841 participants.
  • They judged all studies to be at high risk of bias in at least one domain because most studies used different reference standards, often inappropriate to exclude the presence of the target condition, and the time interval between the index test and the reference standard was rarely defined.
  • Regarding applicability, we judged 15% (5/34) of studies to be at low concern and 85% (29/34) of studies to be at high concern, mostly owing to the characteristics of the participants, most of whom were on waiting lists for orthotopic liver transplantation, and due to pathology of the explanted liver being the only reference standard.
  • MRI for hepatocellular carcinoma of any size and stage: sensitivity 84.4% (95% CI 80.1% to 87.9%) and specificity 93.8% (95% CI 90.1% to 96.1%) (34 studies, 4841 participants; low-certainty evidence).
  • MRI for respectable hepatocellular carcinoma: sensitivity 84.3% (95% CI 77.6% to 89.3%) and specificity 92.9% (95% CI 88.3% to 95.9%) (16 studies, 2150 participants; low-certainty evidence).

The observed heterogeneity in the results remains mostly unexplained. The sensitivity analyses, which included only studies with clearly prespecified positivity criteria and only studies in which the reference standard results were interpreted without knowledge of the index test results, showed no variation in the results.

Reference:

How accurate are magnetic resonance imaging (MRI) scans for detecting liver cancer? By Nadarevic T, et al. published in the Cochrane.

https://www.cochrane.org/CD014798/LIVER_how-accurate-are-magnetic-resonance-imaging-mri-scans-detecting-liver-cancer



Tags:    
Advertisement
Article Source : Cochrane

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News